1.
|
Phase: Phase IV
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other, Pharmaceutical / Industry
Protocol IDs: SPRI-P04445, EU-20654, NCT00266799, SPRI-PELICAN
|
|
2.
|
Phase: Phase III, Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: D-0140, NCT00169104
|
|
3.
|
Phase: Phase III, Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 to 85
Sponsor: Other
Protocol IDs: 20050113, NCT00243685
|
|
4.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: Any age
Sponsor: Other
Protocol IDs: IBCSG-27-02, BIG-1-02, EU-20320, NCT00074152, NSABP-B-37, EUDRACT-2005-001484-64
|
|
5.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: Postmenopausal
Sponsor: NCI
Protocol IDs: SWOG-S0226, CAN-NCIC-MAC7, S0226, NCT00075764
|
|
6.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: XRP9881B/3001, NCT00081796
|
|
7.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: DOXIL-BCA-3001, NCT00091442
|
|
8.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: E7389-G000-301, NCT00337103
|
|
9.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCCTG-N0574, N0574, ACOSOG-N0574, NCT00377156
|
|
10.
|
Phase: Phase III
Type: Diagnostic, Treatment
Status: Active
Age: Not specified
Sponsor: NCI
Protocol IDs: SWOG-S0500, S0500, CALGB-SWOG-S0500, NCT00382018
|
|
11.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: NCI
Protocol IDs: CALGB-40302, NCT00390455
|
|
12.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: A6181094, NCT00373256
|
|
13.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 to 85
Sponsor: Other
Protocol IDs: 06-692, NCT00418457
|
|
14.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: A6181114, NCT00428220
|
|
15.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: A6181099, NCT00435409
|
|
16.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: NCI
Protocol IDs: ECOG-E1105, E1105, NCT00520975
|
|
17.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: TOC4129g, WO20698, NCT00567190
|
|
18.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: CR014764, NCT00580112
|
|
19.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: NCI
Protocol IDs: CALGB-40503, CALGB 40503, NCT00601900
|
|
20.
|
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: Other, Pharmaceutical / Industry
Protocol IDs: CAN-NCIC-MA31, MA31, GSK-EGF108919, EUDRACT-2007-004568-27, NCT00667251
|
|
21.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: CP12-0606, TRI0-CIRG-012, TRI0-012, NCT00703326
|
|
22.
|
Phase: Phase III
Type: Natural history/Epidemiology, Treatment
Status: Active
Age: 18 and over
Sponsor: NCI
Protocol IDs: CALGB-40502, CALGB 40502, NCT00785291
|
|
23.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: 3144A2-3003, NCT00777101
|
|
24.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: SCRI BRE 145, TITAN, NCT00789581
|
|
25.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: TDM4370g, 2008-005 713-22, NCT00829166
|
